(Q30350045)

20 June 2017

1 reference

1 reference

title

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. (English)

1 reference

20 June 2017

0 references

0 references

Scheen AJ

1

1 reference

20 June 2017

1 December 2004

1 reference

20 June 2017

Diabetes and Metabolism

1 reference

20 June 2017

30

1 reference

20 June 2017

6

1 reference

20 June 2017

487-496

1 reference

Diabetes, hypertension, and cardiovascular disease: an update

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Antihypertensive therapy and incidence of type 2 diabetes: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

CAPPP trial. Captopril Prevention Project

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

The prevention or delay of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Insulin resistance in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Insulin resistance and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Insulin resistance in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Functional class in patients with heart failure is associated with the development of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Physiology and pathophysiology of the adipose tissue renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970146-5

7 January 2021

10.1016/S1262-3636(07)70146-5

Identifiers

DOI

1 reference

20 June 2017

1 reference

PubMed ID

15671918